About Hemicentin-1
Hemicentin-1 (HMCN1) is a protein
from Homo sapiens identified by UniProt accession
Q96RW7, 5635 residues long.
MolForge cross-references it against 0 known binders and
157 disease associations.
Target properties
| Protein name | Hemicentin-1 |
|---|
| UniProt accession | Q96RW7 |
|---|
| Gene | HMCN1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 5635 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (5635 residues)
MISWEVVHTV FLFALLYSSL AQDASPQSEI RAEEIPEGAS TLAFVFDVTG SMYDDLVQVI EGASKILETS LKRPKRPLFN FALVPFHDPE IGPVTITTDP KKFQYELREL YVQGGGDCPE MSIGAIKIAL EISLPGSFIY VFTDARSKDY RLTHEVLQLI QQKQSQVVFV LTGDCDDRTH IGYKVYEEIA STSSGQVFHL DKKQVNEVLK WVEEAVQASK VHLLSTDHLE QAVNTWRIPF DPSLKEVTVS LSGPSPMIEI RNPLGKLIKK GFGLHELLNI HNSAKVVNVK EPEAGMWTVK TSSSGRHSVR ITGLSTIDFR AGFSRKPTLD FKKTVSRPVQ GIPTYVLLNT SGISTPARID LLELLSISGS SLKTIPVKYY PHRKPYGIWN ISDFVPPNEA FFLKVTGYDK DDYLFQRVSS VSFSSIVPDA PKVTMPEKTP GYYLQPGQIP CSVDSLLPFT LSFVRNGVTL GVDQYLKESA SVNLDIAKVT LSDEGFYECI AVSSAGTGRA QTFFDVSEPP PVIQVPNNVT VTPGERAVLT CLIISAVDYN LTWQRNDRDV RLAEPARIRT LANLSLELKS VKFNDAGEYH CMVSSEGGSS AASVFLTVQE PPKVTVMPKN QSFTGGSEVS IMCSATGYPK PKIAWTVNDM FIVGSHRYRM TSDGTLFIKN AAPKDAGIYG CLASNSAGTD KQNSTLRYIE APKLMVVQSE LLVALGDITV MECKTSGIPP PQVKWFKGDL ELRPSTFLII DPLLGLLKIQ ETQDLDAGDY TCVAINEAGR ATGKITLDVG SPPVFIQEPA DVSMEIGSNV TLPCYVQGYP EPTIKWRRLD NMPIFSRPFS VSSISQLRTG ALFILNLWAS DKGTYICEAE NQFGKIQSET TVTVTGLVAP LIGISPSVAN VIEGQQLTLP CTLLAGNPIP ERRWIKNSAM LLQNPYITVR SDGSLHIERV QLQDGGEYTC VASNVAGTNN KTTSVVVHVL PTIQHGQQIL STIEGIPVTL PCKASGNPKP SVIWSKKGEL ISTSSAKFSA GADGSLYVVS PGGEESGEYV CTATNTAGYA KRKVQLTVYV RPRVFGDQRG LSQDKPVEIS VLAGEEVTLP CEVKSLPPPI ITWAKETQLI SPFSPRHTFL PSGSMKITET RTSDSGMYLC VATNIAGNVT QAVKLNVHVP PKIQRGPKHL KVQVGQRVDI PCNAQGTPLP VITWSKGGST MLVDGEHHVS NPDGTLSIDQ ATPSDAGIYT CVATNIAGTD ETEITLHVQE PPTVEDLEPP YNTTFQERVA NQRIEFPCPA KGTPKPTIKW LHNGRELTGR EPGISILEDG TLLVIASVTP YDNGEYICVA VNEAGTTERK YNLKVHVPPV IKDKEQVTNV SVLLNQLTNL FCEVEGTPSP IIMWYKDNVQ VTESSTIQTV NNGKILKLFR ATPEDAGRYS CKAINIAGTS QKYFNIDVLV PPTIIGTNFP NEVSVVLNRD VALECQVKGT PFPDIHWFKD GKPLFLGDPN VELLDRGQVL HLKNARRNDK GRYQCTVSNA AGKQAKDIKL TIYIPPSIKG GNVTTDISVL INSLIKLECE TRGLPMPAIT WYKDGQPIMS SSQALYIDKG QYLHIPRAQV SDSATYTCHV ANVAGTAEKS FHVDVYVPPM IEGNLATPLN KQVVIAHSLT LECKAAGNPS PILTWLKDGV PVKANDNIRI EAGGKKLEIM SAQEIDRGQY ICVATSVAGE KEIKYEVDVL VPPAIEGGDE TSYFIVMVNN LLELDCHVTG SPPPTIMWLK DGQLIDERDG FKILLNGRKL VIAQAQVSNT GLYRCMAANT AGDHKKEFEV TVHVPPTIKS SGLSERVVVK YKPVALQCIA NGIPNPSITW LKDDQPVNTA QGNLKIQSSG RVLQIAKTLL EDAGRYTCVA TNAAGETQQH IQLHVHEPPS LEDAGKMLNE TVLVSNPVQL ECKAAGNPVP VITWYKDNRL LSGSTSMTFL NRGQIIDIES AQISDAGIYK CVAINSAGAT ELFYSLQVHV APSISGSNNM VAVVVNNPVR LECEARGIPA PSLTWLKDGS PVSSFSNGLQ VLSGGRILAL TSAQISDTGR YTCVAVNAAG EKQRDIDLRV YVPPNIMGEE QNVSVLISQA VELLCQSDAI PPPTLTWLKD GHPLLKKPGL SISENRSVLK IEDAQVQDTG RYTCEATNVA GKTEKNYNVN IWVPPNIGGS DELTQLTVIE GNLISLLCES SGIPPPNLIW KKKGSPVLTD SMGRVRILSG GRQLQISIAE KSDAALYSCV ASNVAGTAKK EYNLQVYIRP TITNSGSHPT EIIVTRGKSI SLECEVQGIP PPTVTWMKDG HPLIKAKGVE ILDEGHILQL KNIHVSDTGR YVCVAVNVAG MTDKKYDLSV HAPPSIIGNH RSPENISVVE KNSVSLTCEA SGIPLPSITW FKDGWPVSLS NSVRILSGGR MLRLMQTTME DAGQYTCVVR NAAGEERKIF GLSVLVPPHI VGENTLEDVK VKEKQSVTLT CEVTGNPVPE ITWHKDGQPL QEDEAHHIIS GGRFLQITNV QVPHTGRYTC LASSPAGHKS RSFSLNVFVS PTIAGVGSDG NPEDVTVILN SPTSLVCEAY SYPPATITWF KDGTPLESNR NIRILPGGRT LQILNAQEDN AGRYSCVATN EAGEMIKHYE VKVYIPPIIN KGDLWGPGLS PKEVKIKVNN TLTLECEAYA IPSASLSWYK DGQPLKSDDH VNIAANGHTL QIKEAQISDT GRYTCVASNI AGEDELDFDV NIQVPPSFQK LWEIGNMLDT GRNGEAKDVI INNPISLYCE TNAAPPPTLT WYKDGHPLTS SDKVLILPGG RVLQIPRAKV EDAGRYTCVA VNEAGEDSLQ YDVRVLVPPI IKGANSDLPE EVTVLVNKSA LIECLSSGSP APRNSWQKDG QPLLEDDHHK FLSNGRILQI LNTQITDIGR YVCVAENTAG SAKKYFNLNV HVPPSVIGPK SENLTVVVNN FISLTCEVSG FPPPDLSWLK NEQPIKLNTN TLIVPGGRTL QIIRAKVSDG GEYTCIAINQ AGESKKKFSL TVYVPPSIKD HDSESLSVVN VREGTSVSLE CESNAVPPPV ITWYKNGRMI TESTHVEILA DGQMLHIKKA EVSDTGQYVC RAINVAGRDD KNFHLNVYVP PSIEGPEREV IVETISNPVT LTCDATGIPP PTIAWLKNHK RIENSDSLEV RILSGGSKLQ IARSQHSDSG NYTCIASNME GKAQKYYFLS IQVPPSVAGA EIPSDVSVLL GENVELVCNA NGIPTPLIQW LKDGKPIASG ETERIRVSAN GSTLNIYGAL TSDTGKYTCV ATNPAGEEDR IFNLNVYVTP TIRGNKDEAE KLMTLVDTSI NIECRATGTP PPQINWLKNG LPLPLSSHIR LLAAGQVIRI VRAQVSDVAV YTCVASNRAG VDNKHYNLQV FAPPNMDNSM GTEEITVLKG SSTSMACITD GTPAPSMAWL RDGQPLGLDA HLTVSTHGMV LQLLKAETED SGKYTCIASN EAGEVSKHFI LKVLEPPHIN GSEEHEEISV IVNNPLELTC IASGIPAPKM TWMKDGRPLP QTDQVQTLGG GEVLRISTAQ VEDTGRYTCL ASSPAGDDDK EYLVRVHVPP NIAGTDEPRD ITVLRNRQVT LECKSDAVPP PVITWLRNGE RLQATPRVRI LSGGRYLQIN NADLGDTANY TCVASNIAGK TTREFILTVN VPPNIKGGPQ SLVILLNKST VLECIAEGVP TPRITWRKDG AVLAGNHARY SILENGFLHI QSAHVTDTGR YLCMATNAAG TDRRRIDLQV HVPPSIAPGP TNMTVIVNVQ TTLACEATGI PKPSINWRKN GHLLNVDQNQ NSYRLLSSGS LVIISPSVDD TATYECTVTN GAGDDKRTVD LTVQVPPSIA DEPTDFLVTK HAPAVITCTA SGVPFPSIHW TKNGIRLLPR GDGYRILSSG AIEILATQLN HAGRYTCVAR NAAGSAHRHV TLHVHEPPVI QPQPSELHVI LNNPILLPCE ATGTPSPFIT WQKEGINVNT SGRNHAVLPS GGLQISRAVR EDAGTYMCVA QNPAGTALGK IKLNVQVPPV ISPHLKEYVI AVDKPITLSC EADGLPPPDI TWHKDGRAIV ESIRQRVLSS GSLQIAFVQP GDAGHYTCMA ANVAGSSSTS TKLTVHVPPR IRSTEGHYTV NENSQAILPC VADGIPTPAI NWKKDNVLLA NLLGKYTAEP YGELILENVV LEDSGFYTCV ANNAAGEDTH TVSLTVHVLP TFTELPGDVS LNKGEQLRLS CKATGIPLPK LTWTFNNNII PAHFDSVNGH SELVIERVSK EDSGTYVCTA ENSVGFVKAI GFVYVKEPPV FKGDYPSNWI EPLGGNAILN CEVKGDPTPT IQWNRKGVDI EISHRIRQLG NGSLAIYGTV NEDAGDYTCV ATNEAGVVER SMSLTLQSPP IITLEPVETV INAGGKIILN CQATGEPQPT ITWSRQGHSI SWDDRVNVLS NNSLYIADAQ KEDTSEFECV ARNLMGSVLV RVPVIVQVHG GFSQWSAWRA CSVTCGKGIQ KRSRLCNQPL PANGGKPCQG SDLEMRNCQN KPCPVDGSWS EWSLWEECTR SCGRGNQTRT RTCNNPSVQH GGRPCEGNAV EIIMCNIRPC PVHGAWSAWQ PWGTCSESCG KGTQTRARLC NNPPPAFGGS YCDGAETQMQ VCNERNCPIH GKWATWASWS ACSVSCGGGA RQRTRGCSDP VPQYGGRKCE GSDVQSDFCN SDPCPTHGNW SPWSGWGTCS RTCNGGQMRR YRTCDNPPPS NGGRACGGPD SQIQRCNTDM CPVDGSWGSW HSWSQCSASC GGGEKTRKRL CDHPVPVKGG RPCPGDTTQV TRCNVQACPG GPQRARGSVI GNINDVEFGI AFLNATITDS PNSDTRIIRA KITNVPRSLG SAMRKIVSIL NPIYWTTAKE IGEAVNGFTL TNAVFKRETQ VEFATGEILQ MSHIARGLDS DGSLLLDIVV SGYVLQLQSP AEVTVKDYTE DYIQTGPGQL YAYSTRLFTI DGISIPYTWN HTVFYDQAQG RMPFLVETLH ASSVESDYNQ IEETLGFKIH ASISKGDRSN QCPSGFTLDS VGPFCADEDE CAAGNPCSHS CHNAMGTYYC SCPKGLTIAA DGRTCQDIDE CALGRHTCHA GQDCDNTIGS YRCVVRCGSG FRRTSDGLSC QDINECQESS PCHQRCFNAI GSFHCGCEPG YQLKGRKCMD VNECRQNVCR PDQHCKNTRG GYKCIDLCPN GMTKAENGTC IDIDECKDGT HQCRYNQICE NTRGSYRCVC PRGYRSQGVG RPCMDINECE QVPKPCAHQC SNTPGSFKCI CPPGQHLLGD GKSCAGLERL PNYGTQYSSY NLARFSPVRN NYQPQQHYRQ YSHLYSSYSE YRNSRTSLSR TRRTIRKTCP EGSEASHDTC VDIDECENTD ACQHECKNTF GSYQCICPPG YQLTHNGKTC QDIDECLEQN VHCGPNRMCF NMRGSYQCID TPCPPNYQRD PVSGFCLKNC PPNDLECALS PYALEYKLVS LPFGIATNQD LIRLVAYTQD GVMHPRTTFL MVDEEQTVPF ALRDENLKGV VYTTRPLREA ETYRMRVRAS SYSANGTIEY QTTFIVYIAV SAYPY
Explore Hemicentin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets